OVID Ovid Therapeutics Inc.

2.89
+0.04  (+1%)
Previous Close 2.85
Open 2.84
Price To Book 2.26
Market Cap 158,112,831
Shares 54,710,322
Volume 735,723
Short Ratio
Av. Daily Volume 618,384
Stock charts supplied by TradingView

NewsSee all news

  1. Ovid Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results, Provides Corporate Update for 2020

    Multiple clinical data readouts across Ovid's pipeline expected in 2020Completed financings in the fourth quarter strengthening the balance sheet NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics

  2. Ovid Therapeutics Announces Multiple Presentations at the American Academy of Neurology 2020 Annual Meeting

    NEW YORK, March 05, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today

  3. Ovid Therapeutics Names Alexander Kolevzon, M.D., to Scientific Advisory Board

    NEW YORK, March 02, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today

  4. Ovid Therapeutics to Present at the Cowen and Company 40th Annual Health Care Conference

    NEW YORK, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today

  5. Ovid Therapeutics Provides 2020 Update in Preparation for Multiple Clinical Data Readouts Across Rare Neurological Disease Platform

    OV101 (gaboxadol) in Neurodevelopmental Disorders: Topline Results From Pivotal Phase 3 NEPTUNE Trial in Angelman Syndrome Expected in Mid-2020Results From Phase 2 Signal-Finding ROCKET Trial and SKY ROCKET

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 top-line data due early 2Q 2020.
OV101 (ROCKET)
Fragile X syndrome
Phase 2 open label additional data to be presented at AAN meeting April 28, 5:30 – 6:30 p.m. ET.
OV935 ENDYMION
Developmental and Epileptic Encephalopathies (dEE)
Phase 3 data due mid-2020.
OV101 - NEPTUNE
Adolescents with Angelman syndrome
Phase 2 top-line data due 3Q 2020.
TAK-935/OV935 (ELEKTRA)
Dravet Syndrome / Lennox-Gastaut Syndrome
Phase 1b/2a data due 1Q 2020.
TAK-935/OV935 - ARCADE
CDKL5 Deficiency

Latest News

  1. Ovid Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results, Provides Corporate Update for 2020

    Multiple clinical data readouts across Ovid's pipeline expected in 2020Completed financings in the fourth quarter strengthening the balance sheet NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics

  2. Ovid Therapeutics Announces Multiple Presentations at the American Academy of Neurology 2020 Annual Meeting

    NEW YORK, March 05, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today

  3. Ovid Therapeutics Names Alexander Kolevzon, M.D., to Scientific Advisory Board

    NEW YORK, March 02, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today

  4. Ovid Therapeutics to Present at the Cowen and Company 40th Annual Health Care Conference

    NEW YORK, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today

  5. Ovid Therapeutics Provides 2020 Update in Preparation for Multiple Clinical Data Readouts Across Rare Neurological Disease Platform

    OV101 (gaboxadol) in Neurodevelopmental Disorders: Topline Results From Pivotal Phase 3 NEPTUNE Trial in Angelman Syndrome Expected in Mid-2020Results From Phase 2 Signal-Finding ROCKET Trial and SKY ROCKET

  6. Ovid Therapeutics to Participate at the 31st Annual Piper Jaffray Healthcare Conference

    NEW YORK, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today

  7. Ovid Therapeutics Appoints Jason Tardio as Chief Commercial Officer

    Seasoned CNS and Rare Disease Commercial Executive Further Strengthens Executive Management Team NEW YORK, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed

  8. Ovid Therapeutics Reports Third Quarter 2019 Financial Results and Recent Progress

    Announced Positive Initial Results from the Ongoing ENDYMION trial with OV935 (Soticlestat) in Rare Epilepsies; Sustained and Progressively-Improving Median Seizure Frequency Reduction with Prolonged Treatment in

  9. Ovid Therapeutics Announces Senior Management Promotions in Preparation for Multiple Data Readouts Expected in 2020

    Amit Rakhit, M.D., MBA, Promoted to President Timothy Daly Promoted to Executive Vice President, Finance NEW YORK, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company

  10. Ovid Therapeutics Announces Pricing of $32.5 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock

    NEW YORK, Oct. 04, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of patients with rare neurological diseases,

  11. Ovid Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock

    NEW YORK, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of patients with rare neurological diseases,

  12. Ovid Therapeutics Announces Positive Initial Data from Ongoing ENDYMION Open-Label Extension Trial of Soticlestat in People with Rare Epilepsies

    Sustained and Progressively-Improving Median Seizure Frequency Reduction Reaching 84-90% with Prolonged Treatment of Soticlestat in this Difficult-to-Treat Patient Population Soticlestat Continues to Advance in Rare

  13. Ovid Therapeutics Announces First Patient Randomized in Pivotal Phase 3 NEPTUNE Trial of OV101 for the Treatment of Angelman Syndrome

    NEW YORK, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today

  14. Ovid Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    NEW YORK, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today

  15. Ovid Therapeutics Announces Participation in Two Upcoming Investor Conferences

    NEW YORK, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today